1 |
Giocoechea M, García de Vinuesa S, Quiroga B, Verdalles U,Barraca D, Yuste C, et al. 2012. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J. Nephrol. 25: 969-975.
DOI
ScienceOn
|
2 |
Hernández E, Correa A, Bucio L, Souza V, Kershenobich D, Gutiérrez-Ruiz MC. 2002. Pentoxifylline diminished acetaldehyde-induced collagen production in hepatic stellate cells by decreasing interleukin-6 expression. Pharmacol. Res. 46: 435-443.
DOI
ScienceOn
|
3 |
Kasap B, Türkmen M, Kiray M, Kuralay F, Soylu A, Tuğyan K, Kavukçu S. 2013. Effects of pentoxifylline on gentamicininduced nephrotoxicity. Ren. Fail. 35: 1376-1381.
DOI
ScienceOn
|
4 |
Kim JD, Kang YK. 2013. 2012 National Health Insurance Statistical Yearbook, pp. 557 National Health Insurance Service, Health Insurance Review & Assessment Service, Seoul.
|
5 |
Lee SY, Kim SI, Choi ME. 2014. Therapeutic targets for treating fibrotic kidney diseases. Transl. Res. DOI: 10.1016/ j.trsl.2014.07.010.
DOI
|
6 |
Magnusson M, Gunnarsson M, Berntorp E, Björkman S, Höglund P. 2008. Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy human. Eur. J. Pharmacol. 581: 290-295.
DOI
ScienceOn
|
7 |
Modzelewski B, Janiak A. 2004. Pentoxyphilline as a cyclooxygenase (cox-2) inhibitor in experimental sepsis. Med. Sci. Monit. 10: BR233-BR237.
|
8 |
Ortega LM, Fornoni A. 2010. Role of cytokines in the pathogenesis of acute and chronic kidney disease, glomerulonephritis, and end-stage kidney disease. Int. J. Interferon Cytokine Mediator Res. 2: 49-62.
DOI
|
9 |
Bacher A, Eggensperger E, Koppensteiner R, Mayer N, Klimscha W. 2005. Pentoxifylline attenuates the increase in whole blood viscosity after transfusion. Acta Anaesthesiol. Scand. 49: 41-46.
DOI
ScienceOn
|
10 |
Berk B, Akgün H, Erol K, Sirmagül B, Gao ZG, Jacobson KA. 2005. New 8-substituted xanthine derivatives as potent bronchodilators. Farmaco 60: 974-980.
DOI
ScienceOn
|
11 |
Bohm L, Theron T, Binder A. 2000. Influence of pentoxifylline, A-802710, propentofylline and A-802715 (Hoechst) on the expression of cell cycle blocks and S-phase content after irradiation damage. Bioch. Biophys. Acta 1499: 1-10.
DOI
ScienceOn
|
12 |
Bhat VB, Madyastha KM. 2001. Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Biochem. Biophys. Res. Commun. 288: 1212-1217.
DOI
ScienceOn
|
13 |
Çakmak SK, Çakmak A, Gönül M, Kiliç A, Gül Ü. 2012. Pentoxifylline use in dermatology. Inflamm. Allergy Drug Targets 11: 422-432.
DOI
|
14 |
Chung AC, Lan HY. 2011. Chemokines in renal injury. J. Am. Soc. Nephrol. 22: 802-809.
DOI
ScienceOn
|
15 |
Cugini D, Azzollini N, Gagliardini E, Cassis P, Bertini R, Colotta F, et al. 2005. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int. 67: 1753-1761.
DOI
ScienceOn
|
16 |
Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ. 2006. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuria primary glomerular disease. Kidney Int. 69: 1410-1415.
DOI
|
17 |
Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD. 2005. Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int. 67: 1812-1820.
DOI
ScienceOn
|
18 |
Zhou Q, Zheng F, Hou F. 2009. Inhibition of tubulointerstitial fibrosis by pentoxifylline is associated with improvement of vascular endothelial growth factor expression. Acta Phamacol. Sin. 30: 98-106.
DOI
ScienceOn
|
19 |
Ozer MK, Asci H, Oncu M, Yesilot S, Savran M, Bayram D, Cicek E. 2009. Effects of pentoxifylline on amikacin-induced nephrotoxicity in rats. Ren. Fail. 31: 134-139.
DOI
ScienceOn
|
20 |
Wang W, Zolty E, Falk S, Basava V, Reznikov L, Schrier R. 2006. Pentoxifylline protects against endotoxin-induced acute renal failure in mice. Am. J. Physiol. Renal Physiol. 291: F1090-F1095.
DOI
|